WARNINGS
Cardiac Failure and Other Cardiac Effects
Patients with New York Heart Association (NYHA) Class III and IV cardiac status were not studied during clinical trials; therefore, ACTOS is not recommended in these patients (see PRECAUTIONS,
arterial
retinopathy (13.1%), myocardial infarction (8.8%),
vascular disease (6.4%),
In this study two of the 191 patients receiving 15 mg ACTOS plus insulin (1.1%) and two of the 188 patients receiving 30 mg ACTOS plus insulin (1.1%) developed congestive heart failure compared with none of the 187 patients on insulin therapy alone. All four of these patients had previous histories of cardiovascular conditions including coronary artery disease, previous CABG procedures, and myocardial infarction. Analysis of data from this study did not identify specific factors that predict increased risk of congestive heart failure on combination therapy with insulin.
PRECAUTIONS
General
ACTOS exerts its antihyperglycemic effect only in the presence of insulin. Therefore, ACTOS should not be used in patients with
